MarketWatch
US · 3 hrs ago
Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.
Do you trust MarketWatch?
Sign in to rate
Discussion
?
No comments yet — be the first to start the discussion!